Response Rates | Gemcitabine +Cisplatin | Gemcitabine + Carboplatin |
Overall | N = 21 | N = 24 |
Progression #(%) | 10 (63) | 7(44) |
Complete response #(%) | 2(13) | 3(19) |
Partial response #(%) | 2(13) | 3(19) |
Stable disease #(%) | 2(13) | 3(19) |
Discontinued due to toxicity #(%) | 5(24) | 8(33) |
Objective response rate (PR + CR + SD) #(%) | 6(38) | 9(56) |
Mean time to progression (months) [# ± SD (Range)] p = 0.03 | 7.2 [±2(3.2–9.7)] | 5.1 [±1.7(2.3–7.2)] |
Response Rates | Gemcitabine +Cisplatin | Gemcitabine + Carboplatin |
Platinum Sensitive | N = 10 | N = 17 |
Progression #(%) | 6(75) | 4(33) |
Complete response #(%) | 1(13) | 3(25) |
Partial response #(%) | 0(0) | 3(25) |
Stable disease #(%) | 1(13) | 2(17) |
Discontinued due to toxicity #(%) | 2(20) | 5(29) |
Objective response rate (PR + CR + SD) #(%) p = 0.05 | 2(25) | 8(67) |
Mean time to progression (months) [# ± SD (Range)] | 7.2 [±2.5(3.2–9.5)] | 5.1 [±1.8(2.3–7.2)] |
Response Rates | Gemcitabine +Cisplatin | Gemcitabine + Carboplatin |
Platinum Resistant | N = 10 | N = 7 |
Progression #(%) | 3(43) | 3(75) |
Complete response #(%) | 1(14) | 0(0) |
Partial response #(%) | 2(29) | 0(0) |
Stable disease #(%) | 1(14) | 1(25) |
Discontinued due to toxicity #(%) | 3(30) | 3(75) |
Objective response rate (PR + CR + SD) #(%) | 4(57) | 1(25) |
Mean time to progression (months) [# ± SD (Range)] | 7.2 [±1.6(5.7–9.7)] | 5.1 [±1.8(2.5–6.8)] |